INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24401, 30167, 'Salbutamol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24402, 30168, 'Salbutamol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24403, 30234, 'Salbutamol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24404, 115, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24405, 1812, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24406, 4659, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24407, 4660, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24408, 7990, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24409, 7991, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24410, 9136, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24411, 10151, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24412, 10153, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24413, 10156, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24414, 12195, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24415, 12201, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24416, 12203, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24417, 12204, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24418, 13560, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24419, 15510, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24420, 15511, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24421, 15526, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24422, 15530, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24423, 16240, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24424, 22561, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24425, 26458, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24426, 26460, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24427, 29115, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24428, 29116, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24429, 29118, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24430, 29127, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24431, 29128, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24432, 29131, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24433, 29134, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24434, 29231, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24435, 30167, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24436, 30168, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24437, 30234, 'Salbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24438, 0, 'Rotigotine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24439, 0, 'Rotigotine', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24440, 0, 'Rotigotine', 'Asthma', 'Rotigotine (transdermal patch) contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.  Sulfite sensitivity is seen more frequently in people with asthma than people without it.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24441, 0, 'Rotigotine', 'Cardiovascular Diseases', 'Some patients treated with rotigotine exhibited an increased pulse, greater than 100 beats per minute, while supine or standing.  Also, like other dopaminergic agents, rotigotine might impair the systemic regulation of blood pressure causing postural/orthostatic hypotension, especially during dose escalation.  These findings of blood pressure and heart rate elevations should be considered when treating patients with cardiovascular disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24442, 0, 'Rotigotine', 'Water-Electrolyte Imbalance', 'Patients taking rotigotine had a higher incidence of weight gain associated with fluid retention, when compared with patients taking placebo.  Weight gain and fluid retention should be monitored in patients using rotigotine, specially in those with concomitant illnesses as congestive heart failure and renal insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24443, 22863, 'Rubella virus vaccine', 'Immune Deficiency Disease', 'In general, the use of measles, mumps, and rubella vaccine or any single component is contraindicated in patients with primary or acquired immunodeficiency.  Since these vaccines contain live attenuated viruses, the absence of immune competence may potentiate the replication of vaccine virus, increase adverse host reactions, and compromise serum antibody response.  Likewise, the vaccine should not be administered to anyone with a family history of congenital or hereditary immunodeficiency until the individual''s immune status can be assessed and is determined to be adequate.  In the case of HIV infection, patients without overt clinical manifestations suggesting severe immunodeficiency should be vaccinated because measles can be particularly severe and potentially fatal in the presence of HIV.  However, immunization may be less effective in these patients, and they should be monitored for vaccine-preventable diseases.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24444, 22863, 'Rubella virus vaccine', 'Infections', 'Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure.  However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient''s symptoms and their etiology.  Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial.  In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished.  On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered.  In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops.  In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24445, 10014, 'Rosiglitazone', 'Myocardial Infarction', 'Safety data from a pooled analysis of 42 randomized, controlled clinical studies suggest that patients treated with rosiglitazone may have an increased risk of myocardial infarction and/or death from heart-related causes.  The overall incidence of myocardial ischemia was 1.99% in patients receiving rosiglitazone-containing therapies (n = 8,604) for at least 24 weeks, compared to 1.51% in patients receiving placebo or other antidiabetic therapies (n = 5,633) for a similar duration.  The hazard ratio was 1.31 (95% CI, 1.01 to 1.70) for rosiglitazone-treated patients relative to the comparators, which represents a greater than 30% excess risk of myocardial ischemic events in the rosiglitazone group.  However, other published and unpublished data from long-term clinical trials of rosiglitazone provide contradictory evidence about the potential risks.  Until more data are available, caution may be advisable when rosiglitazone is prescribed to patients with underlying heart disease or a history of myocardial infarction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24446, 10014, 'Rosiglitazone', 'Heart Failure', 'The use of thiazolidinediones, alone or in combination with other antidiabetic agents, has been associated with fluid retention and new onset or exacerbation of heart failure.  An increased risk of cardiovascular events (heart failure worsening; new or worsening edema; new or worsening dyspnea; increases in heart failure medication; myocardial infarction; angina; cardiovascular hospitalization and deaths) has been reported with rosiglitazone therapy in type II diabetic patients with New York Heart Association (NYHA) Class I or II congestive heart failure compared to placebo.  Likewise, overnight hospitalization for CHF was observed in 9.9% of diabetic patients with NYHA Class II and III heart failure on pioglitazone compared to 4.7% of patients on glyburide.  An increased incidence of cardiovascular adverse events including edema and cardiac failure has also been reported in patients receiving a thiazolidinedione in combination with insulin relative to insulin and placebo.  Therapy with thiazolidinediones should be administered cautiously and initiated at the lowest recommended dosage in patients with congestive heart failure.  Thiazolidinediones are contraindicated for the treatment of patients with NYHA Class III or IV cardiac status.  Patients should be monitored for signs of worsening heart failure such as increased dyspnea, edema, and weight gain.  Therapy should be discontinued if any deterioration in cardiac status occurs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24447, 10014, 'Rosiglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24448, 10014, 'Rosiglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24449, 10014, 'Rosiglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24450, 10014, 'Rosiglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24451, 10014, 'Rosiglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24452, 10014, 'Rosiglitazone', 'Weight Gain', 'Thiazolidinediones can cause dose-related weight gain, which may be undesirable in obese patients attempting to lose weight.  The mechanism of weight gain is unclear but probably involves a combination of fluid retention and fat accumulation.  In postmarketing experience with rosiglitazone, there have been reports of unusually rapid increases in weight, greater than those generally observed in clinical trials.  Patients who experience such increases should be assessed for fluid retention and volume-related events such as excessive edema and congestive heart failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24453, 10014, 'Rosiglitazone', 'Anemia', 'Thiazolidinediones can cause slight decreases in hemoglobin and hematocrit.  In clinical studies, hemoglobin levels were reduced primarily within the first 4 to 12 weeks of therapy but remained relatively constant thereafter.  These changes may be related to increased plasma volume and have rarely been associated with any significant hematologic clinical effects.  Nevertheless, caution may be advisable when thiazolidinediones are prescribed to patients with certain anemias.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24454, 1257, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24455, 1260, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24456, 8501, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24457, 8502, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24458, 14175, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24459, 31398, 'Baclofen', 'Kidney Diseases', 'Baclofen is primarily eliminated by the kidney.  Patients with impaired renal function may be at greater risk for adverse effects from baclofen due to decreased drug clearance.  Therapy with baclofen should be administered cautiously in such patients.  Dosage adjustments may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24460, 1257, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24461, 1260, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24462, 8501, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24463, 8502, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24464, 14175, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24465, 31398, 'Baclofen', 'Autonomic Dysreflexia', 'Therapy with intrathecal baclofen should be administered cautiously in patients with a history of autonomic dysreflexia, since the presence of nociceptive stimuli or abrupt withdrawal of the medication may trigger an episode of dysreflexia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24466, 1257, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24467, 1260, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24468, 8501, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24469, 8502, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24470, 14175, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24471, 31398, 'Baclofen', 'Psychotic Disorders', 'Baclofen may precipitate or exacerbate psychotic symptoms, both during therapy and following abrupt withdrawal of the drug.  Therapy with baclofen should be administered cautiously in patients with a history of psychiatric disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24472, 1257, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24473, 1260, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24474, 8501, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24475, 8502, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24476, 14175, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24477, 31398, 'Baclofen', 'Epilepsy', 'Deterioration in seizure control and electroencephalographic (EEG) changes have been reported occasionally in epileptic patients treated with baclofen.  Therapy with baclofen should be administered cautiously in patients with a history of seizures.  Clinical status and EEG should be monitored at regular intervals during treatment.  Except in cases of overdose or severe adverse reactions, cessation of baclofen therapy, whenever necessary, should occur gradually with incrementally reduced dosages.  Abrupt withdrawal has been associated with central nervous system effects including seizures, hallucinations, and psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24478, 0, 'Rufinamide', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24479, 0, 'Rufinamide', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24480, 0, 'Rufinamide', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24481, 0, 'Rufinamide', 'Short Qt Syndrome', 'Rufinamide can cause shortening of the QT interval.  Its use is contraindicated in patients with Familial Short QT syndrome as this condition is associated with increased risk of sudden death and ventricular arrhythmias, particularly ventricular fibrillation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24482, 0, 'Rucaparib', 'Hepatic Insufficiency', 'Based on population pharmacokinetic analyses no dose adjustment is recommended for patients with mild hepatic impairment.  Caution should be exercised when using this agent in patients with moderate to severe hepatic impairment as the pharmacokinetics of rucaparib in these patients are unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24483, 0, 'Rucaparib', 'Myelodysplastic Syndromes', 'Cases of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) have been reported with the use of rucaparib.  It is recommended to monitor complete blood count at baseline and monthly thereafter, and as clinically appropriate.  Do not start rucaparib until patients have recovered from hematological toxicity caused by previous chemotherapy.  It might be necessary to interrupt therapy with rucaparib until blood counts have recovered.  If MDS/AML is confirmed, rucaparib should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24484, 0, 'Rucaparib', 'Kidney Diseases', 'No dose adjustment is recommended for patients with mild to moderate renal impairment.  Caution should be exercised when using this agent in patients with severe renal impairment or patients on dialysis as the pharmacokinetics of rucaparib in these patients are unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24485, 0, 'Salsalate', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24486, 0, 'Salsalate', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24487, 0, 'Salsalate', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24488, 0, 'Salsalate', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24489, 0, 'Salsalate', 'Blood Coagulation Disorders', 'All salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially if given in high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24490, 0, 'Salsalate', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24491, 0, 'Salsalate', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24492, 0, 'Salsalate', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24493, 14899, 'Balsalazide', 'Kidney Diseases', 'The use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus.  Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies.  Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease.  Renal function should be evaluated prior to initiation of therapy and periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24494, 21497, 'Sapropterin', 'Gastritis', 'During clinical studies with sapropterin, gastritis was reported as a serious adverse reaction.  Monitor patients for signs and symptoms of gastritis during treatment, and use with caution in patients with a history of gastritis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24495, 21498, 'Sapropterin', 'Gastritis', 'During clinical studies with sapropterin, gastritis was reported as a serious adverse reaction.  Monitor patients for signs and symptoms of gastritis during treatment, and use with caution in patients with a history of gastritis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24496, 21497, 'Sapropterin', 'Liver Failure', 'Patients with liver impairment have not been evaluated in clinical trials with sapropterin.  Hepatic damage has been associated in patients with impaired phenylalanine metabolism.  Caution and monitoring is advised in patients with liver impairment who are receiving treatment with sapropterin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24497, 21498, 'Sapropterin', 'Liver Failure', 'Patients with liver impairment have not been evaluated in clinical trials with sapropterin.  Hepatic damage has been associated in patients with impaired phenylalanine metabolism.  Caution and monitoring is advised in patients with liver impairment who are receiving treatment with sapropterin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24498, 21497, 'Sapropterin', 'Nervous System Diseases', 'A 10-year sapropterin postmarketing-marketing safety surveillance program for a non-phenylketonuria indication, showed that a few patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability especially when coadministered with levodopa.  Patients with neurological disorders, especially those receiving levodopa should be monitored for changes in neurological status during treatment with sapropterin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24499, 21498, 'Sapropterin', 'Nervous System Diseases', 'A 10-year sapropterin postmarketing-marketing safety surveillance program for a non-phenylketonuria indication, showed that a few patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability especially when coadministered with levodopa.  Patients with neurological disorders, especially those receiving levodopa should be monitored for changes in neurological status during treatment with sapropterin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (24500, 21497, 'Sapropterin', 'Kidney Diseases', 'Patients with renal impairment have not been evaluated in sapropterin clinical trials.  Monitor patients who have renal impairment carefully if receiving treatment with sapropterin.', '2', '', 'DDInter', 0);
